Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Luminari

Showing results (81-90 of 210) with videos related to

Pageof 21
Sort By:
Haematologica|May 15, 2025
Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamabGianluigi Ardissino, Piera Angelillo, Maria Cristina Mancuso, et al.
American Journal of Hematology|January 12, 2008
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemiasMaria Goldaniga, Andrea Ferrario, Sergio Cortelazzo, et al.
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Frontiers in Nutrition|May 24, 2021
Prognostic Impact of Muscle Quantity and Quality and Fat Distribution in Diffuse Large B-Cell Lymphoma PatientsGiulia Besutti, Fulvio Massaro, Efrem Bonelli, et al.
Haematologica|February 13, 2008
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up studyStefano Sacchi, Luigi Marcheselli, Alessia Bari, et al.
Computer Methods and Programs in Biomedicine|November 4, 2019
Texture analysis and multiple-instance learning for the classification of malignant lymphomasMarco Lippi, Stefania Gianotti, Angelo Fama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring systemLuca Baldini, Maria Goldaniga, Andrea Guffanti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei LinfomiLuca Baldini, Maura Brugiatelli, Stefano Luminari, et al.
European Journal of Haematology|February 3, 2006
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 studyMassimo Federico, Stefano Luminari, Paolo G Gobbi, et al.
Leukemia & Lymphoma|April 11, 2003
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)Marco Lombardo, Fortunato Morabito, Francesco Merli, et al.
Pageof 21

Showing results (81-90 of 210) with videos related to

Sort By:
Pageof 21
Haematologica|May 15, 2025
Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamabGianluigi Ardissino, Piera Angelillo, Maria Cristina Mancuso, et al.
American Journal of Hematology|January 12, 2008
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemiasMaria Goldaniga, Andrea Ferrario, Sergio Cortelazzo, et al.
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Frontiers in Nutrition|May 24, 2021
Prognostic Impact of Muscle Quantity and Quality and Fat Distribution in Diffuse Large B-Cell Lymphoma PatientsGiulia Besutti, Fulvio Massaro, Efrem Bonelli, et al.
Haematologica|February 13, 2008
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up studyStefano Sacchi, Luigi Marcheselli, Alessia Bari, et al.
Computer Methods and Programs in Biomedicine|November 4, 2019
Texture analysis and multiple-instance learning for the classification of malignant lymphomasMarco Lippi, Stefania Gianotti, Angelo Fama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring systemLuca Baldini, Maria Goldaniga, Andrea Guffanti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei LinfomiLuca Baldini, Maura Brugiatelli, Stefano Luminari, et al.
European Journal of Haematology|February 3, 2006
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 studyMassimo Federico, Stefano Luminari, Paolo G Gobbi, et al.
Leukemia & Lymphoma|April 11, 2003
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)Marco Lombardo, Fortunato Morabito, Francesco Merli, et al.
Pageof 21